Document:

<PAGE>
                                                                   Exhibit 10.44

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [Intentionally Redacted]. A complete version of the
exhibit has been filed separately with the Securities and Exchange Commission.

                  GENERIC DRUG MARKETING AND SUPPLY AGREEMENT

      THIS AGREEMENT is made and entered into on the 20th day of November 2003,

      BY AND BETWEEN

      FDC LIMITED, a company incorporated under the provisions of the Companies
      Act, 1956, having its Corporate office at 142-48 S.V. Road, Jogeshwari
      (W), Mumbai 400 102, India, hereinafter referred to as "FDC", (which term
      shall include its successors and permitted assigns) of the One Part;

                                      AND

      SPECTRUM PHARMACEUTICALS, INC. a corporation organized in accordance with
      the laws of the State of Delaware within the United States of America,
      having its principal office at 157 Technology Drive, Irvine, California,
      USA 92618, hereinafter referred to as "SPECTRUM" (which term shall include
      its successors and permitted assigns) of the Other Part;

      A.    WHEREAS, FDC is currently involved in or intends to be involved in
            the manufacture in India of the drugs mentioned in Appendix 'A', The
            products detailed in the said Appendix 'A' are hereinafter
            collectively referred to as "THE SAID PRODUCTS". As new products
            become available, Appendix 'A' may be amended to incorporate such
            new products as mutually decided by the parties.

      B.    WHEREAS, Spectrum is a pharmaceutical company organized in the
            United States of America ("USA") for the purposes of
<PAGE>
                                       2

            gaining regulatory approval, marketing and distributing products.
            The drugs detailed in the said specific product appendix A are
            hereinafter collectively referred to as "THE SAID PRODUCTS".

      c)    WHEREAS, FDC desires to engage Spectrum to obtain regulatory
            approval from the United States Food and Drug Administration ("FDA")
            to market the said products in the USA, and to market and distribute
            the said products in United States of America; (hereinafter referred
            to as the "Territory").

      Now THEREFORE, for and in consideration of the foregoing premises, and the
      mutual covenants, stipulations, terms and conditions herein contained the
      parties agree as follows:

      1.    APPOINTMENT AND TERRITORIAL LIMITS

      1.1   Subject to the terms and conditions of this Agreement, FDC hereby
            appoints SPECTRUM as its exclusive agent/ distributor for
            registration and the sale of the said-products in United States of
            America and SPECTRUM agrees to exclusively register and market and
            distribute the said products in United States of America in
            accordance with the terms and conditions of this Agreement. FDC
            hereby grants to SPECTRUM an exclusive license to use the
            Intellectual Property Rights associated with the said products to
            the extent necessary for the limited purposes of obtaining
            regulatory approval of the said products in United States of America
            and marketing, distributing and selling the said products in United
            States of America. For the purposes of this Agreement, "Intellectual
            Property Rights" means, collectively, worldwide Patents, Copyrights,
            Trademarks, mask work rights, trade names and all other intellectual
            property rights and proprietary rights, whether arising under the
            laws of the United States or any other state,
<PAGE>
                                       3

            country or jurisdiction, including all rights or causes of action
            for infringement or misappropriation of any of the foregoing. For
            purposes of this Agreement: (a) "Patents" means all patent rights
            and all right, title and interest in all letters patent or
            equivalent rights and applications, including provisional
            applications, for letters patent or rights, industrial and utility
            models, industrial designs, petty patents, patents of importation,
            patents of addition, certificates of invention and other government
            issued or granted indicia of invention ownership, including any
            reissue, extension, division, continuation or continuation-in-part
            applications throughout the world; (b) "Trade Secrets" means all
            right, title and interest in all trade secrets and trade secret
            rights arising under common law, state law, federal law or laws of
            foreign countries; (c) "Copyrights" shall mean all copyrights, and
            all other literary property and authorship rights, and all right,
            title, and interest in all copyrights, copyright registrations,
            certificates of copyright and copyrighted interests throughout the
            world; and (d) "Trademarks" means all right, title and interest in
            all trademark, service mark, trade name and trade dress rights
            arising under the common law, state law, federal laws and laws of
            foreign countries, and all right, title, and interest in all
            trademark, service mark, trade name and trade dress applications and
            registrations interests throughout the world. The exclusive rights
            granted to Spectrum to market the said products in United States of
            America will be subject to the Non-performance Clause given in
            Clause 12.3 with respect to any of the said products.

      1.2   It is however agreed and clarified between the Parties hereto that
            the rights of SPECTRUM to act as the agent/distributor of FDC
<PAGE>
                                       4

            shall be initially confined to the territorial limits of United
            States of America and may thereafter extend to other neighboring
            countries with the prior written consent of, and at the sole
            discretion of FDC.

      1.3   It is also agreed and clarified that FDC is free to assign its
            trademark(s) to any person or party outside of United States of
            America, as long as that person or party does not market or intend
            to market the said product(s) carrying such trademark(s) in United
            States of America.

      2.    CONFIDENTIALITY

      2.1   Neither Party shall disclose to any third party any Confidential
            Information which was obtained from the other Party in connection
            with this Agreement. This obligation of secrecy of the Confidential
            Information shall not apply to information which is required to be
            disclosed to governmental agencies for product registration purposes
            or as may be required by applicable law or Governmental authority
            having competent jurisdiction over the receiving Party. In addition,
            the secrecy obligation shall expire for Confidential Information
            which:

            a)    is or ceases to be Confidential Information as a consequence
                  of authorized disclosures;

            b)    was already in the possession of a Party at the time of
                  receipt from the disclosing Party, as shown by documentary
                  evidence;

            c)    after the date of this Agreement is received from a third
                  party whose direct or indirect source is not the disclosing
                  party.

            For the purpose of this Article, the term "CONFIDENTIAL INFORMATION"
            shall mean any information or data (including
<PAGE>
                                       5

            but not limited to any technical or non-technical data, and any
            formula, patents, methods, processes, patterns, compilation,
            programs, device or technique) that derive economic value, actual or
            potential, from not being generally known to other persons.
            Confidential Information would also include all information
            exchanged by and between the Parties in relation to this Agreement
            or otherwise marked as confidential by any Party to this Agreement.

      2.2.  The Parties agree: (a) to exercise the same degree of care and
            protection (but no less than a reasonable degree of care and
            protection) with respect to each other's Confidential Information as
            a Party would exercise with respect to its own confidential
            information; and (b) except as expressly authorized by this
            Agreement, or as necessary to the performance of the obligations
            hereunder, not to directly or indirectly disclose, copy, transfer,
            or allow access to the Confidential Information. Without limitation
            to the generality of the foregoing, all persons with access to the
            Confidential Information will be subject to the same restrictions
            and limitations as that of the Parties to this Agreement. The
            Parties shall ensure that appropriate non-disclosure undertakings
            are obtained in this regard. Provided that obtaining of such
            non-disclosure undertakings shall not absolve any of the Parties
            hereto from any breach that may be committed by reason of a breach
            by any of the persons to whom the Confidential Information has been
            disclosed pursuant to this Agreement.

      2.3.  The obligations contained in this Article shall survive the duration
            of this Agreement and thereafter for a period of five(5) years or
            until the expiration of all Patents for the said products (including
            any extended term), whichever is later.

      2.4.  Without prejudice to any other provision of this Agreement, the
            Parties acknowledge and agree that any violation of this Article 2
<PAGE>
                                       6

            by a Party would cause the other Party irreparable injury for which
            such other would have no adequate remedy at law, and that such
            other Party shall be entitled to preliminary and other injunctive
            relief against the defaulting Party for any such violation. Such
            injunctive relief will be in addition to, and in no way a limitation
            of, any and all other remedies or rights that such other Party shall
            have at law or in equity.

      3.    OBLIGATIONS OF FDC

      3.1.  FDC hereby agrees:

      a)    That it will take all reasonable care to hold and keep in force all
            manufacturing licenses and permission in respect of the said
            products and comply with requirements of all laws applicable to the
            said products.

      b)    To provide SPECTRUM, with all necessary documents required to enable
            the regulatory approval of the said products by the FDA and SPECTRUM
            shall render all assistance to FDC for registration of the said
            products in the name of FDC. All data, information, notes,
            documents, dossiers, knowledge, formulae, Intellectual Property
            Rights, etc provided by FDC to Spectrum in terms of this Agreement
            shall for at all times and forever remain the exclusive property of
            FDC.

      c)    It is clarified between the parties that all the product
            registrations and the ANDA'S for the said Products in the Territory
            shall be obtained by Spectrum in the name of FDC and the product
            registrations for the said Products, shall for all times and forever
            shall remain the sole and exclusive property of FDC, and Spectrum
            shall not have any claim, right, title or interest of whatsoever in
            the same.
<PAGE>
                                       7

      d)    It is hereby clarified and agreed to by and between the Parties that
            the costs of such regulatory approval, incurred in the United
            States, for the said products, shall be borne solely and exclusively
            by SPECTRUM.

      e)    To provide all technical information and documents in respect of the
            said products as may be required to facilitate regulatory approval,
            distribution and marketing of the said products by SPECTRUM in
            United States of America. FDC will also provide to Spectrum a
            protocol or method of assay of all ingredients. The stability or
            shelf-life of finished products will be for a minimum of 2 years. It
            is hereby clarified and agreed to by and between the Parties that
            the costs of producing and providing such technical information for
            the said products shall be borne solely and exclusively by FDC.

      f)    To manufacture the said Products from time to time, either directly
            or indirectly through any of its subsidiaries or group companies or
            any other third parties in such quantities as may be required to
            enable the fulfillment of the orders placed by SPECTRUM from time to
            time.

      g)    To maintain high standards in manufacturing the said products, and
            to produce quality products as per quality specifications
            established by FDC, confirming to B.P./U.S.P. Pharmaceutical
            specifications.

      h)    To comply with the applicable US regulations contained in 21 CFR -
            Sections 210 and 211, to the extent the same is not contrary to
            provisions of Indian law.
<PAGE>
                                       8

      (i)   To procure the raw material for the manufacture of the said products
            from the suppliers whose manufacturing plants have been approved by
            the FDA, as applicable.

      j)    FDC will carryout all manufacturing/packaging activities in the
            manufacturing facilities duly approved by the FDA, whether such
            facilities be of FDC or any subsidiary, group concern or any other
            person in India.

      k)    Any deficiencies noted during an FDA audit, of the
            manufacturing/packaging plant in India will be remedied immediately
            by FDC and the total cost of such remediation shall be borne by FDC.

      3.2   RECORDS AND REPORTS

      a)    FDC shall ensure that all Records that may reasonably be expected to
            relate to any regulatory process in the United States that may be
            applicable to the said Product from time to time, or that have been
            or may reasonably be expected to be used to support any regulatory
            submission made by SPECTRUM in the United States or elsewhere
            related to the said Product, are maintained as statutorily required,
            and in any event for a period of not less than 7 years following the
            completion of the applicable regulatory process, unless the parties
            hereto unanimously agree otherwise.

      b)    FDC agrees to provide SPECTRUM with copies of such Records required
            to be maintained under Section 3.2(a) as SPECTRUM may reasonably
            request from time to time. All such copies shall be delivered to
            SPECTRUM within twenty-one (21) days of receipt of a request for
            copies.

      c)    FDC and SPECTRUM will jointly identify the drugs/products for the
            US market, depending upon the manufacturing/development
<PAGE>
                                       9

            capabilities of FDC and regulatory approval and sales potential in
            the US. Once the decision has been made the regulatory process for
            filing ANDA will begin by both the companies. FDC will provide to
            SPECTRUM all data and information related to such Product or
            Products as SPECTRUM shall reasonably request that is in the
            possession of FDC or to which FDC has access or rights, in order to
            allow SPECTRUM to assess the Product or Products and prepare an ANDA
            (Abbreviated New Drug Application).

      d)    After the ANDA has been filed and before the ANDA is approved by the
            FDA, FDC and SPECTRUM will agree on a price at which FDC will sell
            the said Product to SPECTRUM, on terms reasonably acceptable to both
            parties, which terms shall be intended to allow each party to obtain
            a usual and customary profit margin from the distribution and sale
            of the Products. Depending upon the competitive landscape and
            pricing by other generic manufacturers flexibility in pricing will
            be essential which will have to be reviewed by both companies
            periodically depending upon the changes in prices for the said drug
            in the market.

      4.    OBLIGATIONS OF SPECTRUM

      4.1.  SPECTRUM hereby agrees at its own cost:

      a)    To comply with all statutory rules, regulations, drug laws and all
            other government regulations affecting the importation and sale of
            the said Products in United States of America.

      b)    To sell/market the said products bought from FDC in accordance with
            marketing rules and regulations applicable in United States of
            America and for this purpose to adopt high marketing standards and
            observe and comply with such reasonable marketing practices as are
            common to marketing such products in United States of America by
            entities of similar size to SPECTRUM. Without prejudice the
            generality of the aforesaid, SPECTRUM shall in its sole
<PAGE>
                                       10

            discretion carry out the sales promotion activities and such other
            activities as are necessary to distribute and market the said
            products in the United States of America.

      c)    To collect and store all market information and data on the sales of
            the said products, including the regions and areas in which the
            sales are higher/lower, the prices at which the sales are being made
            and also to collect such other market data as may be reasonably
            required by FDC from time to time. To provide all such market data
            to FDC on a monthly basis or on such other earlier frequency as may
            be mutually agreed.

      d)    To store the said products in accordance with the product storage
            specifications.

      5.    PRODUCT WARRANTIES AND PRODUCT LIABILITY

      5.1.  FDC hereby represents that the products supplied by them shall be in
            compliance with the USA CGMP regulations, as defined in Title 21 CFR
            parts 210 and 211. FDC represents and warrants that the products,
            their packaging and labeling will not, on the date of delivery into
            the U.S. be adulterated or misbranded, and will otherwise meet all
            applicable specifications established by FDC, confirming to
            B.P./U.S.P. Pharmaceutical specifications.

      5.2.  SPECTRUM may, but will not have an obligation to, carry out such
            tasks or activities as it may desire to test or verify whether the
            said products delivered comply with the specifications. In the
            event of SPECTRUM or its agent being of the view that the products
            do not so comply with the FDA, USA requirements for any reason, then
            in such an event SPECTRUM shall ensure that the products found to be
            non-compliant are not sold or to the customers and FDC is
            immediately notified of
<PAGE>
                                       11

            the same. Such inspection and notification shall be completed within
            a reasonable time not exceeding 60 days from the date of receipt of
            the said products in USA. However all such notices of
            non-compliance shall be subject to verification of the same by the
            representatives of FDC. FDC shall not be required to take back any
            such goods, unless the same has been confirmed by an independent
            laboratory mutually identified to be non-compliant. The decision of
            the independent laboratory in this regard shall be final and
            binding. For the purpose of making any such inspection and
            examination, the representatives of SPECTRUM shall provide full and
            complete co-operation to the designated representative of FDC. ALL
            THE EXPENSES IN CONNECTION WITH LABORATORY TEST TO BE DONE BY THE
            INDEPENDENT LABORATORY WOULD BE BORNE BY THE LOOSING PARTY. SPECTRUM
            shall not be liable to make any payments to FDC with respect to
            products found to be non-compliant at the time of receipt of the
            goods and shall, at FDC's direction, either destroy such products or
            return such products to FDC at FDC's expense.

      6.    TRADEMARKS, PATENTS AND OTHER INTELLECTUAL PROPERTY

      6.1   FDC hereby represents and warrants that it is the owner of all
            Intellectual Property Rights in respect of the said products.

      6.2   In the event that any Patents, Trade Marks, Copyrights, Intellectual
            Property Rights related to the said products being challenged or if
            any infringement proceedings being initiated in the USA either
            against SPECTRUM or FDC in respect of any of the said products, the
            same shall be defended by SPECTRUM at FDC's expense. SPECTRUM shall
            co-operate and provide FDC with all necessary information as may be
            within SPECTRUM'S control and necessary to defend any/all such
            proceedings.
<PAGE>
                                       12

      6.3   In the event of SPECTRUM perceiving any threat to any of the
            Patents, Trade Marks, Copyrights or Intellectual Property Rights of
            FDC or being aware of any third party infringing any of the rights
            of FDC under the Patents held by FDC in respect of the
            said-products, SPECTRUM shall bring the same immediately to the
            attention of FDC. Thereafter, if so reasonably required by FDC,
            SPECTRUM shall initiate such proceedings as may be required by FDC
            to arrest any such infringements. All such proceedings shall be at
            the costs of FDC. In the event that FDC is desirous of taking any
            action against such infringement, then SPECTRUM shall provide all
            commercially reasonable cooperation as may be required by FDC to
            enable FDC to file such proceedings and obtain appropriate reliefs.

      6.4.  SPECTRUM recognizes that, as between SPECTRUM and FDC, the
            Trademarks and/or Copyrights, Intellectual Property Rights in the
            said products as mentioned in the Appendix 'A' are the exclusive
            property of FDC and/or its affiliates. SPECTRUM shall use
            commercially reasonable efforts not do or cause to be done anything
            whereby the rights or reputation of FDC in respect of the said
            Trademarks and/or copyrights of the said products are likely to be
            adversely affected.

      6.5.  Without prejudice to the generality of clause 6.3 above, SPECTRUM
            shall not be entitled to use the said Trademarks, copyrights or any
            Intellectual Property rights, if any, in any manner whatsoever
            without FDC's express permission. SPECTRUM shall also use
            commercially reasonable efforts to ensure that the said Trademarks
            and Copyrights on the packaging of the products imported from FDC
            are not modified, obliterated or altered in any manner whatsoever.
            All marketing, sale and distribution of the said products by
            SPECTRUM shall be deemed to be "use" of the said Trademarks by FDC
            for the purpose of applicable trademark legislation.
<PAGE>
                                       13

      6.6.  Nothing herein contained shall at any time during the term of this
            Agreement or upon expiry or earlier termination thereof be deemed to
            give SPECTRUM any right, claim, interest in the said Trademarks,
            copyright or patent or any Intellectual Property Rights arising in
            terms of this Agreement, in respect to the said products. SPECTRUM
            shall not be entitled to any benefit or right in the said
            Trademarks, copyright or patent as a consequence of any marketing,
            sale or distribution of the said products. It is hereby expressly
            agreed by and between the parties hereto that SPECTRUM shall have no
            right to acquire the said Trademarks, copyright or patent from FDC
            under any circumstances whatsoever by virtue of this Agreement.

      6.7.  SPECTRUM shall render all commercially reasonable assistance to FDC
            as may be required to ensure that the said Trademarks are duly
            registered in the USA in the name of FDC.

      6.8.  SPECTRUM hereby recognizes that although certain of the Trademarks
            related to the said products are unregistered in the USA, as between
            SPECTRUM and FDC, FDC is the owner of the said Trademarks,
            copyrights or patents. In the event of SPECTRUM being aware of any
            infringement of any of the trademarks, copyright or patent or any
            passing off, SPECTRUM shall forthwith intimate the same to FDC.
            Thereafter, if so reasonably required by FDC, SPECTRUM shall
            initiate such proceedings as may be required by FDC to arrest any
            such infringements or to prevent any passing off, including such
            injunctive actions as may be required. All such proceedings shall be
            at the costs of FDC. In the event that FDC is desirous of taking any
            action against such infringement or passing off, then SPECTRUM shall
            provide all commercially reasonable cooperation as may be required
            by FDC to enable FDC to file appropriate proceedings and obtain
            reliefs.
<PAGE>
                                       14

      7.    PLACEMENT OF ORDERS

      7.1.  SPECTRUM shall place written orders with FDC for supply of the
            required said products from time to time, and FDC shall deliver the
            ordered said products at the times and places, and in the amounts,
            specified in such written orders. FDC will require a reasonable time
            of a minimum of 60 days prior estimates of the quantities sought to
            be ordered to enable FDC to supply the same to SPECTRUM.

      8.    PRICES

      8.1.  Generic business is an extremely price sensitive business. Also the
            prices of generic drugs can change rapidly due to many factors that
            are beyond the control of either FDC or SPECTRUM. It is understood
            that FDC will price their drugs in good faith in consultation with
            SPECTRUM and in a manner that the drugs can be sold in the United
            States at a reasonable profit to both the companies. Prices for the
            said products to be supplied will be agreed to after the ANDA has
            been filed and before the ANDA is approved by the FDA, the prices
            will be at a supply price to be mutually decided between the
            parties. Prior to obtaining regulatory approval of each specific
            product in the USA, FDC shall supply to SPECTRUM at no cost such
            quantities of such specific product as SPECTRUM shall reasonably
            require in order to obtain regulatory approval of such specific
            product in the USA.

      8.2.  All prices as agreed to between the Parties shall be CIF (Cost,
            Insurance and Freight Prices). The risk in the said goods shall
            stand transferred to SPECTRUM forthwith on delivery of the goods to
            the port of entry into the USA, whether landed, by sea or by air.
            In the event of any loss of goods in transit, SPECTRUM shall not be
            liable for payment and if such event occurs, FDC
<PAGE>
                                       15

            shall make every reasonable effort to replace the lost goods. In the
            event of any loss of goods in transit subsequent to arrival at the
            USA port of entry, Spectrum shall bear all costs of loss, including
            the liability to pay FDC for the goods subsequent to the port of
            entry into the USA.

      9.    PAYMENTS

      9.1.  Payments for the orders shall be made through irrevocable letters of
            credit to be opened by SPECTRUM through a bank of International
            repute, the branch of which bank is also operating in India, which
            bank is acceptable to FDC. The letters of credit shall be opened in
            favour of FDC prior to the scheduled date of shipment authorizing
            payments to FDC upon presentation of the relevant documents to the
            negotiating bank. The letters of credit shall be opened in favour of
            FDC Limited, 142-48, S.V. Road, Jogeshwari(West), Mumbai- 400 102
            The letters of credit shall be governed by the terms of UCP 500.

      10.   FORCE MAJEURE

      10.1  Neither Party shall be under any liability whatsoever to the other
            for failure or delay in the performance of any of its obligations
            hereunder where such performance becomes impractical by reason of
            any event of Force Majeure (as hereinafter defined).

      10.2. For purposes of this Article, the expression "Force Majeure" shall
            mean war, acts of aggression, civil strife and terrorism, labour
            disputes, including strikes and lockouts, accidents, acts of God,
            shortages of materials, and other inputs, acts of Government,
            failure of networking, viruses, or any other bugs in systems or any
            matter (whether or not of the same nature as
<PAGE>
                                       16

            the foregoing) which are beyond the control of the Party affected by
            such event.

      10.3. In the event a Force Majeure event hinders the performance of this
            Agreement by a Party, the other Party shall be entitled to suspend
            the operation of this Agreement by giving written notice to the
            party who is affected by the event of Force Majeure, if the
            continuance of this Agreement becomes impractical by reason of such
            event of Force Majeure. In the event the event of Force Majeure
            does not subside for a period of sixty days after the notice for
            suspension as aforesaid, the affected party may in its discretion
            choose to forthwith terminate this Agreement by providing notice of
            such termination in writing,

      11.   ASSIGNMENT

      11.1  Neither party shall without the other's prior written consent,
            assign any of its rights or duties hereunder. It is however
            clarified that nothing in this Agreement shall prevent any of the
            parties from performing, sub-contracting any of its obligations
            herein to any of its subsidiaries or group companies, provided that
            the principal responsibility of performance of the terms and
            conditions of this agreement remains and continues to remain on any
            of the parties and all such delegation or sub-contracting is in
            accordance with the other terms and conditions of this Agreement.

      11.2. This Agreement shall be binding on the successors and permitted
            assigns of the parties hereto.

      12.   DURATION AND TERMINATION
<PAGE>
                                       17

      12.1  This Agreement shall remain in effect unless terminated by mutual
            agreement of the Parties; provided, however, that each specific
            product addendum may provide that this Agreement shall terminate
            earlier with respect to the specific product subject to such
            addendum. On termination of this Agreement each parties to the
            Agreement, shall perform their obligations to the orders

      12.2  This Agreement may be terminated by either party if the other party
            commits a breach of any material obligation or any other material
            clause or material requirement of the Agreement, and such breach is
            not rectified within 30 days by the breaching party.

      12.3  This Agreement may be terminated by either party on account of
            non-performance by either of the other parties. Non-performance
            shall be defined as:

            12.3.1. United States Food and Drug Administration (USFDA) approval
            not being received within two (2) years of the filing of an
            application.

            12.3.2. FDC not completing studies necessary and/or not providing
            data necessary to file Abbreviated New Drug Applications (ANDAs) for
            said products within one year of the signing of this agreement.

            12.3.3. Spectrum not filing an ANDA for any said product within six
            (6) months of receiving information described in section 12.3.2.

            12.3.4. Revenue not being generated from the sale of any said
            product within six months of the latter of the approval of the ANDA
            by the USFDA for said product or the expiration of the
<PAGE>
                                       18

            patent and/or any exclusivity period for generic marketing of said
            product.

            12.3.5. If both the Parties mutually are unable to arrive/reach at a
            supply price with respect to the said Product. If the Agreement is
            terminated under this sub-section, then FDC will be prohibited from
            selling the said Product within the Territory, either directly or
            indirectly, for a price below the price last offered by FDC to
            SPECTRUM hereunder.

      13.   APPLICABLE LAW AND DISPUTE RESOLUTION

      13.1  In the event of any disagreement, dispute or conflict between the
            Parties relating to or arising out of the provisions of this
            Agreement that cannot otherwise be resolved promptly by the
            management of SPECTRUM and FDC within a period of thirty days from
            such date of the dispute, disagreement or conflict, the same shall
            be resolved by arbitration.

      13.2  Arbitration will in London as per ICC rules and will be conducted in
            English Language.

      14.   INDEMNIFICATION

      14.1  FDC hereby indemnifies and agrees to defend, save and hold harmless
            SPECTRUM and each of its officers, directors and employees, from and
            against any and all Liabilities, which may be imposed upon or
            incurred by SPECTRUM by reason of:

            (i)   FDC's negligence or willful misconduct in connection with
                  their activities under this Agreement;

            (ii)  FDC's breach of any of the covenants, agreements, warranties
                  and representations made to Spectrum under this Agreement;
<PAGE>
                                       19

            (iii) FDC's said Products not meeting the required specifications
                  established by FDC, confirming to B.P./U.S.P. Pharmaceutical
                  specifications or the requirements of any applicable law or
                  regulation in the territory

      14.2  Spectrum hereby indemnifies and agrees to defend, save and hold
            harmless FDC and each of its officers, directors and employees, from
            and against any and all Liabilities which may be imposed upon or
            incurred by FDC by reason of:

            (i)   Spectrum's negligence or willful misconduct in connection
                  with their activities under this Agreement;

            (ii)  Spectrum's breach of any of the covenants, agreements,
                  warranties and representations made to FDC under this
                  Agreement;

            (iii) SPECTRUM'S importation, handling, storage, use, distribution,
                  marketing and selling the said Product in the United States of
                  America in violation of this Agreement or the requirements of
                  any applicable laws or regulations of the Territory.

      14.3  For purposes of this Article 14 Liabilities means any and all
            claims, actions, suits, losses, liabilities, penalties, costs,
            charges and expenses (including, without limitation, attorney's
            fees, expert witness fees and other costs of suit).

      15    MODIFICATION

            This Agreement shall not be subject to modification, except by
            modification in writing, signed by the parties, or their legal
            agents or representatives. This Agreement may not be varied except
            by written agreement duly executed by all parties hereto.
<PAGE>
                                       20

      16.   This Agreement is on a principal to principal basis. Except to the
            extent herein expressly provided, neither party is an agent of the
            other. The relationship created between FDC and Spectrum under this
            Agreement shall be that of seller and purchaser. Except to the
            extent Spectrum may act as agent for FDC in connection with the
            filing and processing of one or more ANDAs as herein contemplated,
            Spectrum and its Affiliates shall under no circumstances be deemed
            to be agents, representatives, partners or employees of FDC.

      17.   NOTICES

            All notices, letters and communications between the Parties shall be
            in writing. Any notices, letters or communications to be given
            pursuant to this Agreement shall be given only if transmitted by
            Telefax or electronic delivery subject to acknowledgement of
            electronic delivery by the recipient. The notice shall be deemed to
            be received only on the date of acknowledgement of electronic
            delivery, on the date of transmission by Telefax if such
            transmission is confirmed as having been successfully received ,or
            on the date of actual delivery by an internationally known courier
            service. Addresses for notice are as follows:

            FOR: Spectrum Pharmaceuticals, Inc.
            157 Technology Drive
            Irvine, CA
            92618
            U.S.A.
            Attention: Dr. R. Shrotriya Chairman and CEO
<PAGE>
                                       21

            Telephone: (949) 743-9247
            Telefax:   (949) 788-6706
            Email: rshrotriya@spectrumpharm.com

            FOR: FDC Limited
            142-48, S.V. Road
            Jogeshwari(West)
            Mumbai- 400 102
            India
            Attention: Mr. Nandan M. Chandavarkar
                       Director
            Telephone: (009122) 26780652
            Fax.:      (009122) 26788123
            Email: nandan_c@vsnl.com
                   jogfdc@bom3.vsnl.net.in

            The parties may from time-to-time change their designated addresses,
            telephone numbers and person/s to whom notice should be sent, by
            sending to the other party a notice in accordance with the above
            sub-paragraph.

            [Signature Page Follows]
<PAGE>
                                       22

                                   Appendix A

                            [Intentionally Redacted]

                            [Intentionally Redacted]

                            [Intentionally Redacted]

[Intentionally Redacted] Certain information on this page has been omitted and
filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
<PAGE>
                                       23

IN WITNESS WHEREOF, the parties hereto have signed this Agreement on the date
set forth below.
For and on behalf of FDC

By: /s/ M.A. Chandavarkar
    ------------------------------------
    M.A. Chandavarkar, Managing Director
Date: November 20th, 2003
Place: Mumbai, India

For and on behalf of Spectrum Pharmaceuticals, Inc
By: /s/ Rajesh Shrotriya
    ------------------------------------
Rajesh Shrotriya, Chief Executive Officer

Date: November 20th, 2003
Place: Irvine, California, U.S.A<PAGE>
                                                                   EXHIBIT 10.45

                         EXECUTIVE EMPLOYMENT AGREEMENT

         THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered
into as of October 22, 2001 by and between, Dr. Luigi Lenaz, currently residing
at 11 Planetree Court, Newton, Pennsylvania 18940 (hereinafter referred to as
"Executive"), and NeoTherapeutics, Inc. (hereinafter referred to as
"Corporation").

         WHEREAS:

             A.   The Corporation is a corporation organized under the laws of
                  the State of Delaware, and is engaged in the business of
                  developing and manufacturing pharmaceutical products and
                  services ; and

             B.   Executive is a person whose skills, experience and training
                  are required by the Corporation; and

             C.   Executive wishes to accept the employment offered by the
                  Corporation on the terms and conditions hereinafter set forth.

         NOW THEREFORE, the parties hereto, intending to be legally bound, do
         hereby agree as follows:

         1.       EMPLOYMENT

                  1.1      Position and Duties

                           The Corporation does hereby employ Executive and
                  Executive hereby accepts such employment as Vice President
                  Oncology Division of the Corporation upon the terms and
                  provisions set forth in this Agreement. Executive shall report
                  to the President and Chief Operating Officer of the
                  Corporation subject to the directions of the President and
                  Chief Operating Officer. Executive shall devote his full
                  working time and effort to the business and affairs of the
                  Corporation as necessary to faithfully discharge the duties
                  and responsibilities of his office.

                           Executive may participate in other business and act
                  as a director of any profit or nonprofit corporation, so long
                  as such activity is not competitive with the business of the
                  Corporation in any material respect and does not materially
                  detract from the performance of his duties as a full time
                  executive of the Corporation.

         2.       TERM

                  This Agreement shall continue in full force and effective for
         a period (the "Term") which shall commence as of October 22, 2001 (the
         "effective date") and shall continue until July 1, 2003 unless sooner
         terminated as hereafter provided. Thereafter, this Agreement will
         automatically renew for one (1) year periods, unless either party

<PAGE>

         gives to the other written notice at least ninety (90) days prior to
         the commencement of the next year, of such party's intent not to renew
         this Agreement.

         3.       COMPENSATION

                  3.1      Base Salary

                           As compensation for the services to be performed by
                  Executive during the continuance of this Agreement, the
                  Corporation shall pay Executive a base salary of not less than
                  $200,000 per year for each year of his employment hereunder,
                  payable in accordance with Corporation practices in effect
                  from time to time, but not less often than monthly (the "Base
                  Salary"). Base Salary shall be payable in substantially equal
                  installments and reduced on a pro rata basis for any fraction
                  of a year or month during which Executive is not so employed.

                  3.2      Bonus

                           The Board of Directors of the Corporation may, at its
                  sole discretion, award bonuses of cash or stock from time to
                  time. Any such Bonus earned by Executive shall be paid at
                  least annually within ninety (90) days after the conclusion of
                  the Corporation's fiscal year or, upon mutual agreement of the
                  parties, in another fashion.

                  3.3      Additional Benefits

                           Executive shall be entitled to all rights and
                  benefits for which Executive is otherwise entitled under any
                  pension plan, profit sharing plan, life, medical, dental, or
                  benefit the Corporation may provide for senior executives
                  generally and for employees of the Corporation generally from
                  time to time in effect during the term of this Agreement
                  (collectively, "Additional Benefits"). Executive shall receive
                  participation in the Executive Medical Plan and shall commence
                  such participation immediately.

                  3.4      Stock Options

                           As an additional element of compensation to Executive
                  in consideration of the services to be rendered hereunder,
                  Employer shall grant to Executive options to acquire shares of
                  Corporation's common stock at the sole discretion of the Board
                  of Directors as follows:

                                    (A) The specific terms of stock options
                           awarded to Executives shall be as set forth in the
                           separate option agreements. To the extent that
                           Corporation does not have available options in its
                           option plans to grant to Executive as contractually
                           committed herein above, Corporation agrees to amend
                           its plans and/or adopt new plans as promptly as
                           possible to provide sufficient options for such
                           option grants. Corporation shall use its best

                                       2
<PAGE>

                           efforts to prepare and submit for approval by its
                           directors and its stockholders at the 2002 Annual
                           Meeting of Stockholders a new option plan which would
                           provide sufficient options to allow Corporation to
                           meet its contractual obligations to Executive herein
                           and to provide for potential grants of stock options
                           to other key employees.

                                    (B) Executive shall be considered for
                           additional grants of options, SAR's, phantom stock
                           rights and any similar option or securities
                           compensation when and as such grants are considered
                           for other executives or employees of the Corporation,
                           but any grant is wholly at the discretion of the
                           Board.

                                    (C) For all purposes of this Agreement, a
                           "change of control" shall mean and shall be deemed to
                           have occurred if:

                                             (1) There shall be consummated (x)
                                    any consolidation or merger of the
                                    Corporation with another corporation or
                                    entity and as a result of such consolidation
                                    or merger, a majority of the outstanding
                                    voting securities of the surviving or
                                    resulting corporation or entity shall be
                                    owned in the aggregate by persons who were
                                    not stockholders of the Corporation prior to
                                    the merger or consolidation (excluding the
                                    affiliates of the acquiror who acquired
                                    their shares within one hundred eighty (180)
                                    days prior to such merger or transfer (or in
                                    one transaction or a series of related
                                    transactions) of all, or substantially all,
                                    of the assets of the Corporation, or

                                             (2) The stockholders of the
                                    Corporation shall have approved any plan or
                                    proposal for the liquidation or dissolution
                                    of the Corporation; or

                                             (3) Any "person" (as such term is
                                    used in the Sections 13(d) and 14 (d) (2) of
                                    the Securities Exchange Act of 1934), shall
                                    have become the beneficial owner (within the
                                    meaning of Rule 13d-3 under the Exchange
                                    Act) of forty percent (40%) or more of the
                                    Corporation's outstanding common stock,
                                    without the prior approval of the Board, or

                                             (4) During any period of two (2)
                                    consecutive years, individuals who at the
                                    beginning of such period constituted the
                                    entire Board of Directors shall have ceased
                                    for any reason to constitute a majority
                                    thereof unless the election, or the
                                    nomination for election by the Corporation's
                                    stockholders, of each new Director was
                                    approved by vote of the Directors then still
                                    in office who were Directors at the
                                    beginning of the period.

                                        3
<PAGE>

                                    (D) Retirement of Executive

                                             Any options held by Executive will
                                    become fully vested at the time that
                                    Executive terminates employment due to his
                                    retirement. Retirement is defined as the
                                    voluntary termination of employment by the
                                    Executive as a result of the Executive
                                    having reached age 65, or, subsequent to
                                    thereto, voluntarily terminates his
                                    employment.

                  3.5      Periodic Review

                           The Corporation shall review Executive's Base Salary
                  bonus, Stock Options, and Additional Benefits then being
                  provided to Executive not less frequently than every twelve
                  (12) months. Following such review, the Corporation may, in
                  its discretion, increase the Base Salary, award a Bonus, grant
                  Stock Options and Additional Benefits.

                  3.6      Reimbursements

                                    3.6.1 General. Subject to approval of
                           his/her superior, Executives shall be promptly
                           reimbursed by the Corporation for amounts actually
                           expended by Executive in the course of performing
                           duties for the Corporation where Executive tenders
                           receipts or other documentation reasonably
                           substantiating the amounts as required by the
                           Corporation. As a condition of employment hereunder,
                           Executive shall entertain business prospects, provide
                           and maintain an appropriate automobile, maintain and
                           improve Executive's professional skills by
                           participating in continuing education courses and
                           seminars, and maintain memberships in civic groups
                           and professional societies and Corporation agrees to
                           reimburse Executive therefore consistent with
                           criteria under the Internal Revenue Code, subject to
                           approval by their superior.

                                    3.6.2 Business Expenses. During the term of
                           this Agreement to the extent that such expenditures
                           satisfy the criteria under the Internal Revenue Code
                           for deductibility by the Corporation (whether or not
                           fully deductible by the Corporation) for federal
                           income tax purposes as ordinary and necessary
                           business expenses, Corporation agrees to and shall
                           reimburse Executive promptly for all reasonable
                           business expenditures including travel,
                           entertainment, parking, business meetings,
                           professional dues and the costs of and dues
                           associated with maintaining club memberships and
                           expenses of education, made or substantiated in
                           accordance with policies, practices and procedures
                           established from time to time by the Corporation
                           generally with respect to other senior
                           executives/managers and other employees of the
                           Corporation and incurred in the pursuit and
                           furtherance of the Corporation's business and good
                           will.

                                        4
<PAGE>

                                    3.6.3 Travel. In connection with any travel
                           by Executive in the performance of his duties
                           hereunder, Corporation shall advance to Executive an
                           amount equivalent to the reasonable and necessary
                           expenses of such travel and appropriate to
                           Executive's position in Corporation pursuant to the
                           policies and procedures established for this purpose
                           by this Corporation.

                                    3.6.4 Entertainment. Executive shall be
                           expected to entertain those with whom the Corporation
                           conducts business both at Executives' home and at
                           public restaurants, theatres, etc. The Corporation
                           shall pay Executive for or promptly reimburse
                           Executive for the reasonable and necessary costs of
                           such entertainment.

                  3.7      Deductions

                           There shall be deducted from Executive's gross
                  compensation appropriate amounts for standard employee
                  deductions (e.g., income tax withholding, social security and
                  state disability insurance) and any other amounts authorized
                  for deduction by Executive.

         4.       VACATION

                  Executive shall be entitled to not less than four weeks per
         year of paid vacation for each twelve (12) month period of employment
         which shall accrue on a pro rata basis from the date employment
         commences under this Agreement. Subject to the foregoing minimum
         vacation, Executive shall be entitled to paid vacation, holidays and
         leave time in accordance with the plans, policies, programs and
         practices in effect generally with respect to other senior employees of
         the Corporation. Executive shall not forfeit or cease to accrue any
         paid vacation, if he is unable to or does not use it, in any year or
         period of years during the term hereof, or any extensions thereof.

         5.       INDEMNIFICATION

                  The Corporation shall, to the maximum extent permitted by law,
         indemnify and hold Executive harmless from and against any expenses,
         including reasonable attorney's fees, judgements, fines, settlements
         and other amounts actually and reasonably incurred in connection with
         any proceeding arising out of, or related to, Executive's employment by
         the Corporation. The Corporation shall advance to Executive any
         expenses, including reasonable attorneys' fees and costs of settlement,
         reasonably incurred in defending any such proceeding to the maximum
         extent permitted by law. The Corporation will include Executive under
         all directors' and officers' liability insurance policies and will use
         its best efforts to maintain existing coverage levels, assuming
         continuation of insurance availability at commercially reasonable
         rates.

         6.       TERMINATION OF EMPLOYMENT

                                        5
<PAGE>

                  Employment shall terminate upon the occurrence of any of the
                  following events:

                  6.1      Expiration of Term

                           Upon at least ninety (90) days prior written notice
                  by Corporation to Executive terminating this Agreement prior
                  to the expiration of the original term or an extended term as
                  specified in Section 2; upon such termination, Executive shall
                  be entitled to the compensation provided in paragraph 6.4
                  payable as provided therein.

                  6.2      Mutual Agreement

                           Whenever the Corporation and Executive mutually agree
                  in writing to termination;

                  6.3      Termination for Cause

                           At any time for cause. For purposes of this
                  Agreement,"cause" shall be defined as any of the following,
                  provided however, that the board of directors of the
                  Corporation by a duly adopted resolution has determined the
                  presence of such cause in good faith: (i) Executive's material
                  breach of any of his duties and responsibilities under this
                  Agreement (other than as a result of incapacity due to
                  disability); (ii) Executive's conviction by, or entry of a
                  plea of guilty in, a court of competent jurisdiction for a
                  felony; or, (iii) Executive's commission of an act of fraud or
                  willful misconduct or gross negligence in the performance of
                  his duties

                           Notwithstanding the foregoing, Executive shall not be
                  terminated for "cause pursuant to the clauses above, unless
                  and until Executive has received notice of the proposed
                  termination for cause including details on the bases for such
                  termination and has had an opportunity to be heard before at
                  least a majority of members of the board of directors of the
                  Corporation. Executive shall be deemed to have had such an
                  opportunity if written or telephonic notice is given at least
                  ten (10) days in advance of a meeting.

                  6.4      Termination Without Cause

                           Without cause. Notwithstanding any other provision of
                  this section, the Corporation shall have the right to
                  terminate Executive's employment with the Corporation without
                  cause at any time, but any such termination shall be without
                  prejudice to Executive's rights to receive Base Salary and
                  Additional Benefits provided; under this Agreement for the
                  greater of two (2) years or the remaining term, as set forth
                  in paragraph 2 above, of this Agreement and, except as
                  provided in the proviso below, Executive shall be vested in
                  all options granted to him, and shall have one (1) month for
                  each month of Executive's tenure, with a minimum of six (6)
                  months and a maximum of one (1) year, to exercise all vested
                  options; provided, further, if the Board determines that
                  Executive's employment is being

                                        6
<PAGE>

                  terminated for the reason that the shared expectations of
                  Executive and the Board are not being met; in the Board's
                  judgement, then Executive's vesting as shall occur during a
                  period following the date of termination of Executive's
                  employment equal to the number of months of Executive's tenure
                  with the Corporation, with a minimum of six (6) months and a
                  maximum of one (1) year, with the right to exercise for the
                  same period plus thirty (30) days. The continued vesting and
                  exercise rights relative to all options granted to Executive
                  shall be subject to the same limitations as set forth in the
                  immediately preceding sentence. If Executive is terminated
                  without cause, Executive may elect to receive a lump sum
                  payment representing the aggregate cash compensation
                  (including salary, bonus, auto allowance and any other cash or
                  equivalent compensation, other than continued vacation
                  accrual). Such lump sum payment shall be made not later than
                  ten (10) days after Executive makes such election. In the
                  event of such lump sum election, all insurance and other
                  noncash benefits shall cease.

                  6.5      Death/Disability

                           The death or disability of Executive. For the
                  purposes of this Agreement, disability shall mean the absence
                  of Executive performing Executive's duties with the
                  Corporation on a full time basis for a period of six (6)
                  consecutive months, as a result of incapacity due to mental or
                  physical illness which is determined to be total and permanent
                  by a physician selected by the Corporation or its insurers and
                  reasonably acceptable to Executive or Executive's legal
                  representative. If Executive shall become disabled,
                  Executive's employment may be terminated; by written notice to
                  Executive. In the event of the death of Executive, all
                  compensation hereunder shall be paid based on value at time of
                  death.

                  6.6      By Executive Without Cause

                           By Executive at any time upon ninety (90) days'
                  notice to Corporation. Executive shall not be entitled to any
                  severance in the event of such a termination.

         7.       CHANGE OF CONTROL

                  If there should occur a "change of control" of the Corporation
         (or any successor), as defined in paragraph 3.4 (C) hereof, and
         Executive's employment is terminated (other than by Executive) or
         Executive is adversely affected in terms of overall compensation,
         benefits, title, authority, reports reporting relationships, location
         of employment or similar matters, then Executive, without limitation on
         any other rights hereunder, may, within six (6) months after receiving
         notice of such event, elect to resign from full time service to the
         Corporation. In the event of such election by Executive, Executive
         shall be provided with senior executive outplacement services at an
         outplacement or executive search firm of Executive's selection (and
         reasonably acceptable to Corporation), and the cash compensation and
         all benefits to which Executive is entitled hereunder shall be
         discontinued twenty-four (24) months after the date of election (or
         earlier, if a lump sum payment of cash compensation is specified).
         Executive, at his election, shall have the

                                        7
<PAGE>

         right to request and, if requested, shall be paid the full cash value
         of all amounts of cash compensation due for the 24-month period
         (including salary, approved bonus, auto allowance, and any other cash
         or equivalent compensation) in a lump sum, such lump sum payment shall
         be made not later than ten (10) days after Executive gives notice to
         the Corporation of his lump sum election. In the event of such
         election, all insurance and noncash benefits shall cease. All options
         granted to Executive shall vest to the extent provided in paragraph 6.4
         above. In addition, if an acquirer of 100% of the Corporation stock is
         itself a publicly held company, the Corporation shall make reasonable
         efforts to negotiate that Executive shall have the right, but not the
         obligation, to convert all his Corporation vested options into options
         on the acquirer's stock and shall have two (2) years to exercise those
         options, but Corporation shall have no obligation to Executive if it
         fails to secure such rights or concludes that pursuing such rights
         would materially prejudice the interest of the stockholders of the
         Corporation.

         8.       BREAKUP AND DISPOSITION OF CORPORATION ASSETS

                  If within the first year of Executive's employment, the Board
         determines to maximize stockholder value through disposition of a
         significant amount of assets or business units of the Corporation,
         Executive shall assist Corporation through such disposition and shall
         thereafter be entitled to terminate this Agreement within six (6)
         months of such event (completion of such disposition) and receive all
         benefits provided under section 6.4 hereof. As used herein, the term
         "significant amount of assets or business units of the Corporation"
         shall mean either fifty percent (50%) or more of the gross revenues of
         Corporation or, in the absence of gross revenues, 50% of the gross
         assets of the Corporation including intellectual properties, as
         determined by an independent appraisal, or fifty percent (50%) or more
         of the operating income by excluding losses from business units of the
         Corporation which are operating at a loss.)

         9.       BUSINESS DISCLOSURES AND SOLICITATION OF EMPLOYEES

                  Executive agrees during the term of his employment by the
         Corporation and thereafter that he will not disclose, other than to an
         authorized employee, officer, director or agent of the Corporation, any
         information relating to the Corporation's business, trade, practices,
         trade secrets or know-how or proprietary information without the
         Corporation's prior express written consent. Following termination of
         Executive's employment, Executive shall be permitted to continue in his
         usual occupation and shall not be prohibited from competing with the
         Corporation except during the two (2) year severance period and in the
         specific industry market segments in which the Corporation competes and
         which represent twenty percent (20%) or more of its revenues. Executive
         agrees that for a period of one (1) year following the termination of
         Executive's employment with the Corporation for any reason, Executive
         shall not directly or indirectly solicit, induce, recruit or encourage
         any of the Corporation's employees to leave their employment or take
         away such employees to leave their employment or take away such
         employees or attempts to solicit, induce, recruit, encourage or take
         away employees of the Corporation.

         10. MISCELLANEOUS

                                        8
<PAGE>

                  10.1     Arbitration

                           Any dispute, controversy or claim arising out of or
                  in respect of this Agreement (or its validity, interpretation
                  or enforcement), the employment relationship or the subject
                  matter hereof shall, at the request of either party, be
                  settled by binding arbitration in Orange County, California in
                  accordance with the Commercial Arbitration Rules of the
                  American Arbitration Association and judgement upon the award
                  rendered by the arbitrator(s) may be entered in any court
                  having jurisdiction thereof. The parties shall have rights to
                  discovery as provided in section 1283.05 of the California
                  Code of Civil Procedure. The prevailing party in any such
                  matter shall recover all of its costs and expenses, including
                  reasonable attorney's fees.

                  10.2     No Third-Party Beneficiaries

                           This Agreement shall not confer any rights or
                  remedies upon any person other than the parties and their
                  respective successors and permitted assigns.

                  10.3     Entire Agreement

                           This Agreement (including the documents referred to
                  herein) constitutes the entire agreement between the parties
                  and supersedes any prior understandings, agreements, or
                  representations between the parties, written or oral, to the
                  extent they have related in any way to the subject matter
                  hereof.

                  10.4     Succession and Assignment

                           This Agreement shall be binding upon and inure to the
                  benefit of the parties named herein and their respective
                  successors and permitted assigns. No party may assign either
                  the Agreement or any of his or its rights, interests, or
                  obligations hereunder without the prior written approval of
                  the Corporation and Executive; provided, however, that the
                  Corporation may (i) assign any or all of its rights and
                  interests hereunder to one or more of its affiliates and (ii)
                  designate one or more of its affiliates to perform its
                  obligations hereunder (in any or all of which cases the
                  Corporation nonetheless shall remain responsible for the
                  performance of all of its obligations hereunder).

                  10.5     Counterparts

                           This Agreement may be executed in one or more
                  Counterparts, each of which shall be deemed an original but
                  all of which together will constitute one and the same
                  instrument.

                  10.6     Headings

                                        9
<PAGE>

                           The section headings contained in this Agreement are
                  inserted for convenience only and shall not affect in any way
                  the meaning or interpretation of this agreement.

                  10.7     Notices

                           All notices, requests, demands, claims, and other
                  communications required or permitted hereunder will be in
                  writing. Any notice, request, demand, claim, or other
                  communication hereunder shall be deemed duly given if (and
                  then two business days after) it is sent by registered or
                  certified mail, return receipt requested, postage prepaid, and
                  addressed to the intended recipient as set forth below:

                               If to Corporation:

                               NEOTHERAPEUTICS, INC.
                               157 TECHNOLOGY DRIVE
                               IRVINE, CA 92618

                               If to Executive:

                               LUIGI LENAZ, M.D.
                               11 PLANETREE COURT
                               NEWTON, PA 18940

                           Any party may send any notice, request, demand,
                  claim, or other communication hereunder to the intended
                  recipient at the address set forth above using any other means
                  (including personal delivery, expedited courier, messenger
                  service, telecopy, telex, ordinary mail, or electronic mail),
                  but no such notice, request, demand, claim, or other
                  communication shall be deemed to have been duly given unless
                  and until it actually is received by the intended recipient.
                  Any party may change the address to which notices, requests,
                  demands, claims, and other communications hereunder are to be
                  delivered by giving notice in the manner herein set forth.

                  10.8     Governing Law

                           This Agreement shall be governed by, and construed
                  and enforced in accordance with, the laws of the State of
                  California without giving effect to any choice or conflict of
                  law provision or rule (whether of the State of California or
                  any other jurisdiction) that would cause the application of
                  the laws of any jurisdiction other than the State of
                  California.

                  10.9     Amendments and Waivers

                           No amendment of any provision of this Agreement shall
                  be valid unless the same shall be in writing and signed by
                  Corporation and the Executive. No waiver by any party of any
                  default, misrepresentation, or breach of warranty or convenant
                  hereunder, whether intentional or not, shall be deemed to
                  extend to any prior or subsequent default, misrepresentation,
                  or breach of warranty or convenant

                                       10
<PAGE>

                  hereunder or affect in any way any rights arising by virtue of
                  any prior or subsequent such occurrence.

                  10.10    Severability

                           Any term or provision of this Agreement that is
                  invalid or unenforceable in any situation in any jurisdiction
                  shall not affect the validity or enforceability of the
                  remaining terms and provisions hereof or the validity or
                  enforceability of the offending term or provision in any other
                  situation or in any other jurisdiction.

         IN WITNESS THEREOF, the parties hereto have executed this Agreement as
of the date first above written.

                                         "CORPORATION"

                                         By: /s/ ALVIN J. GLASKY
                                             -----------------------------------
                                             Alvin J. Glasky, Ph.D.

                                         Its:  Chief Executive Officer

                                         "EXECUTIVE"

                                         By: /s/ LUIGI LENAZ
                                             -----------------------------------
                                                Luigi Lenaz, M.D.
                                         Title: Vice President Oncology Division

                                       11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]